Rewriting Immune Disease with AI and RNA Therapeutics
Sotirion Biosciences is redefining precision medicine through immune-driven discovery. Our proprietary Sotirion Immune Repertoire Assay (SIRA) uncovers disease-driving immune signatures to guide therapeutic development and companion diagnostics. Using these insights, we apply RNA gene therapy, including RNA trans-splicing, to repair disease-causing mutations without altering genomic DNA, enabling precise treatments for cancer and immune-related diseases.
Powered by SIRA, we profile each patient's immune repertoire to identify the right therapy for the right patient — targeting specific RNA splice variants with unprecedented precision.
Our SIRAFold™ platform integrates multi-omics data and structural modeling to rapidly identify and optimize RNA therapeutics across cancer and genetic disorders.
Harnessing the cell's own spliceosome machinery via SMaRT™ to correct defective transcripts — leaving the genome fully intact.
SIRA forms the foundation of our immune repertoire-based CompanionDx, enabling regulatory co-development of diagnostics alongside our lead RNA therapeutic program.
Three integrated innovations powering the future of RNA medicine
Spliceosome-Mediated RNA Trans-splicing
A breakthrough approach that leverages the cell's own natural machinery to repair defective RNA transcripts — offering a safer alternative to permanent genome editing.
Structural Integrated RNA Analysis & Folding
An AI-driven discovery engine that accelerates RNA therapeutic development by combining cutting-edge machine learning with deep molecular biology insights.
Immune Repertoire-Based Companion Diagnostic Platform
A precision companion diagnostic that profiles the immune repertoire to identify patients most likely to respond to SMaRT™ RNA trans-splicing therapy — bridging the gap between molecular targeting and patient-level response prediction.
Translating our platform science into actionable clinical tools
Immune Repertoire-Based MRD Detection for Blood Cancers
Sotirion's MRD Monitor leverages the Sotirion Immune Repertoire Assay (SIRA) to detect and track minimal residual disease in blood cancers with ultra-high sensitivity. By profiling the clonal architecture of T-cell and B-cell receptors, SIRA identifies residual malignant clones that evade conventional detection methods — enabling earlier intervention and more precise treatment decisions.
Peripheral blood or bone marrow sample is collected and immune cells are isolated for SIRA profiling.
SIRA sequences and characterizes the full T-cell and B-cell receptor repertoire at single-clone resolution.
AI-driven analysis identifies and tracks residual malignant clones — even at extremely low frequencies undetectable by standard methods.
Longitudinal MRD tracking informs treatment response, relapse risk, and therapy adjustments with precision.
Detects residual disease at frequencies as low as 1 in 106 cells — far beyond conventional flow cytometry or PCR-based MRD assays.
Optimized for hematologic malignancies including ALL, CLL, multiple myeloma, and other B- and T-cell lymphomas.
Serial sampling tracks clonal evolution over time, enabling real-time assessment of treatment efficacy and early detection of emerging resistance.
Designed for regulatory co-development as a companion diagnostic alongside Sotirion's SMaRT™ RNA trans-splicing therapies.
Interested in learning more? We'd love to hear from you.
HQ: 20271 Goldenrod Ln
Germantown, MD 20876
Lab: 100 S Jackson Ave Ste 5-100
Pittsburgh, PA 15202
Open to strategic collaborations
Research, clinical, and investment inquiries welcome
Actively seeking Series A investment